[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases, including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. It serves patients worldwide through specialty pharmacies, distributors, hospitals, and clinics.

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. The company markets several approved therapies, such as TRIKAFTA/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX, while advancing a diverse pipeline of innovative treatments across multiple therapeutic areas. 

Fundamentals

See More
  • Market Capitalization, $K 111,268,112
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.30
  • Price/Sales 9.46
  • Price/Cash Flow 25.46
  • Price/Book 5.88

Options Overview Details

View History
  • Implied Volatility 28.92% (+0.45%)
  • Historical Volatility 21.35%
  • IV Percentile 45%
  • IV Rank 28.34%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.51
  • Today's Volume 800
  • Volume Avg (30-Day) 2,508
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 51,113
  • Open Int (30-Day) 49,609
  • Expected Range 426.55 to 426.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.19
  • Number of Estimates 7
  • High Estimate $4.47
  • Low Estimate $3.79
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +4.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
412.27 +3.46%
on 05/05/26
456.68 -6.60%
on 05/14/26
+2.61 (+0.62%)
since 05/01/26
3-Month
412.27 +3.46%
on 05/05/26
507.92 -16.02%
on 03/10/26
-59.50 (-12.24%)
since 03/02/26
52-Week
362.50 +17.66%
on 08/11/25
507.92 -16.02%
on 03/10/26
-18.90 (-4.24%)
since 06/02/25

Most Recent Stories

More News
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 146.26 (-1.07%)
VRTX : 426.43 (-2.73%)
REGN : 594.39 (-1.04%)
AMGN : 325.76 (-1.02%)
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 –

VRTX : 426.43 (-2.73%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

VRTX : 426.43 (-2.73%)
$DOWI : 51,218.46 (+0.27%)
REGN : 594.39 (-1.04%)
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

COO : 59.77 (-0.70%)
VRTX : 426.43 (-2.73%)
CLOV : 3.83 (-2.30%)
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

$SPX : 7,610.46 (+0.14%)
JPM : 301.09 (+1.52%)
VRTX : 426.43 (-2.73%)
BBH : 181.46 (-2.41%)
Vertex to Participate in Upcoming May Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 426.43 (-2.73%)
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

VRTX : 426.43 (-2.73%)
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany-

VRTX : 426.43 (-2.73%)
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

VRTX : 426.43 (-2.73%)
Vertex: Q1 Earnings Snapshot

Vertex: Q1 Earnings Snapshot

VRTX : 426.43 (-2.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 453.82
2nd Resistance Point 448.68
1st Resistance Point 443.54
Last Price 426.43
1st Support Level 433.26
2nd Support Level 428.12
3rd Support Level 422.98

See More

52-Week High 507.92
Fibonacci 61.8% 452.37
Fibonacci 50% 435.21
Last Price 426.43
Fibonacci 38.2% 418.05
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.